Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...
Pharmaceutical Technology on MSN1d
Ono earmarks $940m to gain rare blood cancer therapy from IonisJapan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
Zacks Investment Research on MSN1d
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to OnoIonis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired ...
Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
Ionis Pharmaceuticals (IONS) and Ono Pharmaceutical announced that the two companies have entered into a license agreement in which Ono obtains ...
Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...
Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has entered into a license agreement with Ionis Pharmaceuticals, Inc ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global ...
Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback